Amgen Inc. AMGN
Composite 59/100; the shares have moved about 25% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 35/100 — a moderate mark against it.
Momentum ranks 78/100 — a strong point in its favour. Quality ranks 75/100 — a moderate point in its favour. Growth ranks 67/100 — a moderate point in its favour.
Balance-sheet strength ranks 35/100 — a moderate mark against it. Valuation ranks 41/100 — a slight mark against it.
What the company does Amgen discovers, develops, and markets human therapeutics across immunology, oncology, bone health, and cardiovascular diseases. Key drugs include Enbrel, Repatha, Otezla, and TEPEZZA, with a pipeline spanning 6 Phase 3 weight-loss trials targeting obesity markets dominated by Lilly and Novo Nordisk.
Key financials Amgen posts strong profitability: ROE 101.3%, ROA 8.3%, ROCE 17.5%, and net margins 21.0%. Revenue and EPS growth stand at 5.8% and 4.4%, respectively, with gross margins at 71.4%. The balance sheet shows high leverage (Debt/Equity 6.24) but solid coverage (Interest coverage 4.36).
Stock health Momentum is robust: +15.55% over 3 months, +14.92% over 6 months, and +31.54% over 12 months. RSI(14) at 67.40 signals near-term strength, though the stock is -2.60% below its 52-week high. Sideravia scores Quality 78.8 and Momentum 67.5, but Valuation 39.8 reflects rich pricing.
Price vs fair value The stock trades at a PREMIUM of 12.10% to our fair-value estimate of 340.64 and a PREMIUM of 7.90% to the 12-month target of 357.03. - Analysts highlight bullish projections ahead of Q2 earnings (Zacks) - Simply Wall St notes “still looks below fair value today” - Europe backing expands Repatha use, supporting growth (Simply Wall St) - Motley Fool flags 6 Phase 3 weight-loss trials targeting obesity market share
Looking forward Forward P/E of 17.70 and PEG of 0.33 suggest undemanding valuation relative to growth, though P/E of 27.32 remains elevated. Pipeline catalysts in obesity and expanded Repatha indications could drive upside if clinical and regulatory milestones are met.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.